Stephens analyst Ben Bienvenu said he thinks Pilgrim Pride management's well articulated key customer strategy and operational excellence, which were on display at the company's investor day, should continue to drive value over commodity cycles. Bienvenu adds that he sees the benefit from ASF-driven protein inflation "becoming a when, not if situation for the U.S. market." The analyst, who sees Pilgrim's as best positioned in the near-term among protein companies with Mexico and Europe performing well and the U.S. bar "set appropriately," raised his price target on the stock to $35 from $33 and keeps an Overweight rating on shares.